-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] On May 18, Zhongsheng Pharmaceutical announced that its subsidiary Chia Tai Tianqing signed an agreement with Symhogen A/S, a wholly-owned subsidiary of Servier and a key antibody research and development center, to acquire the latter's LAG -3 Worldwide rights to the monoclonal antibody Sym02Chia Tai Tianqing will pay Symphogen in accordance with the acquisition consideration at closing, and the transaction also involves potential milestone payments related to the sa.
The transaction is subject to closing preconditions and is expected to close in June 202LAG-3, like PD-1, is an immune checkpoi.
In recent years, new drugs around PD-1 targets have been launched continuously, opening a new era of tumor immunotherapy and bringing good news to the majority of patien.
However, the industry also pointed out that clinical studies have shown that PD1 only has long-term efficacy in 10% to 30% of patients, the overall response rate is not high, and there are obvious drug resistance proble.
In this regard, medical researchers are also constantly looking for other potential targets to improve the efficacy of immunothera.
The expansion of indications of LAG-3 monoclonal antibody combined with PD-1 monoclonal antibody is a new direction discovered by researchers and has become a major trend in pharmaceutical research and developme.
Some clinical studies have shown that LAG-3 combined with PD-1 shows great potential, and the drug development prospect is very bro.
It is reported that Sym022 is a fully human recombinant LAG-3 monoclonal antibo.
At present, the product has completed two clinical phase I experimen.
The clinical results show that whether it is used alone or in combination with other tumor immune checkpoint inhibitors, The products all have a good safety profile and tolerabili.
For this acquisition, Zhongsheng Pharmaceutical announced that LAG-3 is a clinically validated tumor immune target, which can further enhance the group's existing tumor research and development pipeline; LAG-3 can be combined with Anlotinib, Aniko, e.
The listed products and pipelines TQB2450 (PD-L1), TQB2618 (TIM3) and other combination drugs have synergistic enhancement effect; and the product has completed the global multi-center phase I clinical trial, and the Group also owns its global rights, which can further promote the company's Global strategic deployme.
According to incomplete statistics in the industry, a total of 22 LAG-3 therapies have entered the clinic worldwide, of which monoclonal antibodies account for nearly 7
The companies involved include Merck, Novartis, Boehringer Ingelheim, GSK and many other multinational pharmaceutical companies and some A powerful local pharmaceutical compa.
Faster progress is Merck's favezelimab (MK-4280), which is in Phase III clinical tria.
The data shows that this product is an anti-LAG-3 antibody under investigation developed by Merck, which can block the interaction between MHC-II receptors and LAG-3, inhibit the up-regulation of LAG-3, and restore T cells to tumo.
Cell killing effe.
During the 2021 ASCO Annual Meeting, Merck announced data from a Phase 1 clinical trial of favezelimab combined with Keytruda in patients with microsatellite stable (MSS) colorectal cancer (CR.
The results showed that in terms of objective response rate (ORR), PD-L1 composite positive score (CPS) ≥ 1 group (n=36) was 11%, CPS<1 group (n=35) was 9%; in disease control rate (DCR), the CPS≥1 group was 31%, and the CPS<1 group was 13%; the median duration of response (DOR) in both groups was 16 mont.
A Phase 3 clinical trial of a fixed-dose combination of Favezelimab and Keytruda has begun in November 2021 to compare the combination with standard of care in patients with metastatic PD-L1-positive previously treated colorectal canc.
In the domestic market, the research and development of LAG-3 is still in the early sta.
A total of 12 LAG-3 antibody products have entered the clinic, and most of them are in the early stage I or I/II clinical tria.
Xinda Biology, Regeneron, Anmai Biology, BeiGene, Henlius,e.
As more pharmaceutical companies deploy in this field, it is foreseeable that LAG-3, a new blue ocean market for medicine, will continue to expa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
The transaction is subject to closing preconditions and is expected to close in June 202LAG-3, like PD-1, is an immune checkpoi.
In recent years, new drugs around PD-1 targets have been launched continuously, opening a new era of tumor immunotherapy and bringing good news to the majority of patien.
However, the industry also pointed out that clinical studies have shown that PD1 only has long-term efficacy in 10% to 30% of patients, the overall response rate is not high, and there are obvious drug resistance proble.
In this regard, medical researchers are also constantly looking for other potential targets to improve the efficacy of immunothera.
The expansion of indications of LAG-3 monoclonal antibody combined with PD-1 monoclonal antibody is a new direction discovered by researchers and has become a major trend in pharmaceutical research and developme.
Some clinical studies have shown that LAG-3 combined with PD-1 shows great potential, and the drug development prospect is very bro.
It is reported that Sym022 is a fully human recombinant LAG-3 monoclonal antibo.
At present, the product has completed two clinical phase I experimen.
The clinical results show that whether it is used alone or in combination with other tumor immune checkpoint inhibitors, The products all have a good safety profile and tolerabili.
For this acquisition, Zhongsheng Pharmaceutical announced that LAG-3 is a clinically validated tumor immune target, which can further enhance the group's existing tumor research and development pipeline; LAG-3 can be combined with Anlotinib, Aniko, e.
The listed products and pipelines TQB2450 (PD-L1), TQB2618 (TIM3) and other combination drugs have synergistic enhancement effect; and the product has completed the global multi-center phase I clinical trial, and the Group also owns its global rights, which can further promote the company's Global strategic deployme.
According to incomplete statistics in the industry, a total of 22 LAG-3 therapies have entered the clinic worldwide, of which monoclonal antibodies account for nearly 7
The companies involved include Merck, Novartis, Boehringer Ingelheim, GSK and many other multinational pharmaceutical companies and some A powerful local pharmaceutical compa.
Faster progress is Merck's favezelimab (MK-4280), which is in Phase III clinical tria.
The data shows that this product is an anti-LAG-3 antibody under investigation developed by Merck, which can block the interaction between MHC-II receptors and LAG-3, inhibit the up-regulation of LAG-3, and restore T cells to tumo.
Cell killing effe.
During the 2021 ASCO Annual Meeting, Merck announced data from a Phase 1 clinical trial of favezelimab combined with Keytruda in patients with microsatellite stable (MSS) colorectal cancer (CR.
The results showed that in terms of objective response rate (ORR), PD-L1 composite positive score (CPS) ≥ 1 group (n=36) was 11%, CPS<1 group (n=35) was 9%; in disease control rate (DCR), the CPS≥1 group was 31%, and the CPS<1 group was 13%; the median duration of response (DOR) in both groups was 16 mont.
A Phase 3 clinical trial of a fixed-dose combination of Favezelimab and Keytruda has begun in November 2021 to compare the combination with standard of care in patients with metastatic PD-L1-positive previously treated colorectal canc.
In the domestic market, the research and development of LAG-3 is still in the early sta.
A total of 12 LAG-3 antibody products have entered the clinic, and most of them are in the early stage I or I/II clinical tria.
Xinda Biology, Regeneron, Anmai Biology, BeiGene, Henlius,e.
As more pharmaceutical companies deploy in this field, it is foreseeable that LAG-3, a new blue ocean market for medicine, will continue to expa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
